<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065349</url>
  </required_header>
  <id_info>
    <org_study_id>8477-CL-0020</org_study_id>
    <secondary_id>2013-002521-27</secondary_id>
    <nct_id>NCT02065349</nct_id>
  </id_info>
  <brief_title>A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety</brief_title>
  <acronym>MOBILE</acronym>
  <official_title>A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects With Peripheral Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the painkilling efficacy of ASP8477 relative to mock
      (placebo) in patients that have been diagnosed with painful diabetic peripheral neuropathy or
      postherpetic neuralgia determined by the change in the average daily pain intensity in
      patients that initially respond favorably to treatment with ASP8477.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of a Screening Period, Single-Blind Treatment Period, Double-Blind
      Randomized Withdrawal Period and Follow-up Period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2014</start_date>
  <completion_date type="Actual">February 13, 2015</completion_date>
  <primary_completion_date type="Actual">February 13, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean of 24-hour average pain intensity, Numeric pain rating scale (NPRS)</measure>
    <time_frame>Baseline of the double-blind randomized withdrawal period to the last 3 days of double-blind randomized withdrawal period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Date of randomization to first 3 consecutive days of double-blind period with an observed treatment failure</time_frame>
    <description>Treatment failure is defined as mean 24 hour pain intensity was equal or more than 4 with at least a 30% increase in pain intensity relative to baseline of the double-blind randomized withdrawal period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate to ASP8477 in the Single-Blind Period</measure>
    <time_frame>Baseline of the single-blind period (last 3 days of the placebo run-in period) to baseline of the double-blind period (last 3 days of the single-blind period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) score</measure>
    <time_frame>From the baseline of the single-blind period to End of Treatment Visit (Day 49 or upon early discontinuation)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by TEAE and SAE, laboratory tests, vital signs, C-SSRS, PWC and MWC scores, Bond-Lader score</measure>
    <time_frame>From Screening to End of Study Visit (13 weeks)</time_frame>
    <description>TEAE=Treatment Emergent Adverse Events, SAE = Serious Adverse Event, C-SSRS = Columbia Suicide Severity Rating Scale, PWC = Physician Withdrawal Checklist, MWC = Marijuana Withdrawal Checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of pharmacokinetics of ASP8477 concentration: Trough concentration (Ctrough), observed maximum concentration (Cmax), Area under the curve (AUC)0-6</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Post-Herpetic Neuralgia (PHN)</condition>
  <condition>Neuropathic Pain</condition>
  <condition>Painful Diabetic Peripheral Neuropathy (PDPN)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP8477</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP8477</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP8477</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PDPN subject must have:

               -  Established diagnosis of diabetes (type I or II) with painful diabetic peripheral
                  neuropathy and glycosylated hemoglobin (HbA1c) ≤ 11% at Screening.

               -  Stable glycemic control (HbA1c ≤ 11%) achieved by a drug regimen for at least 3
                  months prior to Screening.

               -  At least a 1-year history of DPN pain.

               -  Diabetic distal symmetrical polyneuropathy symptoms (including pain) stable for
                  at least the last 3 months prior to Screening based on PI judgment and
                  subject-reported medical history.

          -  PHN subject must have pain present ≥ 6 months after healing of the herpes zoster rash.

        Exclusion Criteria:

          -  Subject has significant pain of an etiology other than PDPN or PHN, or clearly non
             differentiated pain, or plantar fasciitis, heel spurs, tibial neuropathy, Morton's
             neuroma, bunions, metatarsalgia, arthritis in feet, ischemic pain, neurological
             disorders unrelated to diabetic neuropathy, skin condition in area of neuropathy that
             could alter sensation, malignancy, or current orthostatic hypotension, hypo or
             hypertension, syncope or clinically significant ECG, clinical intolerance to
             Non-steroidal anti-inflammatory drugs (NSAIDs) or ASP8477, depression, psychosis or
             psychiatric or neurological illness, BMI of over 35, renal impairment or failure,
             alcohol (ETOH) or drug abuse, GI complaints.

          -  Previous investigational therapy within 28 days or 5 half lives
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site: CZ42003</name>
      <address>
        <city>Chocen</city>
        <zip>561 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CZ42004</name>
      <address>
        <city>Litomysl</city>
        <zip>517 14</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CZ42011</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CZ42014</name>
      <address>
        <city>Praha 2</city>
        <zip>12000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CZ42001</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <zip>516 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: CZ42002</name>
      <address>
        <city>Slezska Ostrava</city>
        <zip>710 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: DE49003</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: DE49005</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: PL48003</name>
      <address>
        <city>Bialystok</city>
        <zip>15-950</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: PL48004</name>
      <address>
        <city>Poznan</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: PL48001</name>
      <address>
        <city>Poznan</city>
        <zip>61-655</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: PL48002</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: PL48005</name>
      <address>
        <city>Warszawa</city>
        <zip>00-465</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: GB44001</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: GB44003</name>
      <address>
        <city>Ipswich</city>
        <zip>IP45PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: GB44006</name>
      <address>
        <city>London</city>
        <zip>SE17EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: GB44002</name>
      <address>
        <city>Manchester</city>
        <zip>M320UT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/study.aspx?ID=217</url>
    <description>Link to results on the Astellas Clinical Study Results website.</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral neuropathy</keyword>
  <keyword>PHN</keyword>
  <keyword>pain</keyword>
  <keyword>PDPN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Pain</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

